140 related articles for article (PubMed ID: 38269047)
1. Characteristics and use of patient-reported outcomes of clinical trials for high-risk neurological medical devices that received FDA premarket approval from 2001 to 2022.
Ryan ME; Srivastava S; Wan L; Yang G; Zhang B
Contemp Clin Trials Commun; 2024 Feb; 37():101254. PubMed ID: 38269047
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
Rathi VK; Krumholz HM; Masoudi FA; Ross JS
JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
[TBL] [Abstract][Full Text] [Related]
3. Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations.
Zhang B; Shankara SB; Guo J; Zhang H
Contemp Clin Trials; 2022 May; 116():106757. PubMed ID: 35398250
[TBL] [Abstract][Full Text] [Related]
4. Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.
Dubin JR; Simon SD; Norrell K; Perera J; Gowen J; Cil A
JAMA Netw Open; 2021 May; 4(5):e217274. PubMed ID: 33956132
[TBL] [Abstract][Full Text] [Related]
5. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
6. Spinal devices in the United States-investigational device exemption trials and premarket approval of class III devices.
Golish SR; Reed ML
Spine J; 2017 Jan; 17(1):150-157. PubMed ID: 27737804
[TBL] [Abstract][Full Text] [Related]
7. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
8. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
Swanson MJ; Johnston JL; Ross JS
Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
[TBL] [Abstract][Full Text] [Related]
9. Design and analysis of crossover trials for investigating high-risk medical devices: A review.
Zhang B; Guo J; Zhang H
Contemp Clin Trials Commun; 2022 Dec; 30():101004. PubMed ID: 36164356
[TBL] [Abstract][Full Text] [Related]
10. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN; Kramer DB; Kesselheim AS
JAMA; 2014 Jan 22-29; 311(4):385-91. PubMed ID: 24449317
[TBL] [Abstract][Full Text] [Related]
11. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
Ghobadi CW; Hayman EL; Finkle JH; Walter JR; Xu S
J Am Coll Radiol; 2017 Jan; 14(1):24-33. PubMed ID: 28061962
[TBL] [Abstract][Full Text] [Related]
12. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
13. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis.
Moon JT; Konstantinidis M; Song N; Nezami N; Majdalany BS; Herr A; Siskin G
J Clin Transl Sci; 2023; 7(1):e67. PubMed ID: 37008598
[TBL] [Abstract][Full Text] [Related]
15. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
16. Study Design and Data Analysis of Artificial Pancreas Device Systems with Closed-Loop Glucose-Sensing Insulin Delivery.
Shankara SB; Liu Y; Zheng Q; Guo J; Wang G; Zhang B
Int J Endocrinol; 2021; 2021():8812695. PubMed ID: 33679974
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FDA-Approved Orthopaedic Devices and Their Recalls.
Day CS; Park DJ; Rozenshteyn FS; Owusu-Sarpong N; Gonzalez A
J Bone Joint Surg Am; 2016 Mar; 98(6):517-24. PubMed ID: 26984921
[TBL] [Abstract][Full Text] [Related]
18. Recalls of Moderate- and High-Risk Otolaryngologic Devices Approved by the US Food and Drug Administration, 2003-2019.
Talati IA; Parsa KM; Gao WZ
Otolaryngol Head Neck Surg; 2022 Nov; 167(5):832-838. PubMed ID: 35290135
[TBL] [Abstract][Full Text] [Related]
19. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
[TBL] [Abstract][Full Text] [Related]
20. Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration Supplements.
Dubin JR; Enriquez JR; Cheng AL; Campbell H; Cil A
JAMA Netw Open; 2023 Apr; 6(4):e237699. PubMed ID: 37043202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
